Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma

European Journal of Haematology

Volumn 74, Issue 5, 2005, Pages 445-447

  Gockel, Henning R ^a   Heidemann, J ^a   Lugering, A ^a   Mesters, R M ^a   Parwaresch, R ^b   Domschke, W ^a   Lugering, N ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Hepatitis B; Liver; Marginal zone B cell lymphoma; Rituximab

Indexed keywords

CD20 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; RITUXIMAB;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CELL CLONE; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; GENE REARRANGEMENT; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER HILUS; LYMPHOID CELL; LYMPHOMA CELL; MALE; PRIORITY JOURNAL; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR REGRESSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; LIVER NEOPLASMS; LYMPHOMA, B-CELL; MALE; TREATMENT OUTCOME;

EID: 17444420691     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00419.x     Document Type: Article

References (6)

1. ISAACSON PG, BANKS PM, BEST PV, MCLURE SP, MULLER-HERMELINK HK, WYATT JI. Primary low-grade hepatic B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)-type. Am J Surg Pathol 1995;19:571-575.
2. REFF ME, CARNER K, CHAMBERS KS, CHINN PC, LEONARD JE, RAAB R, NEWMAN RA, HANNA N, ANDERSON DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
3. HAINSWORTH JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003;30:9-15.
4. GRILLO-LOPEZ AJ, HEDRICK E, RASHFORD M, BENYUNES M. Rituximab: ongoing and future clinical development. Semin Oncol 2002;29:105-112.
5. HAINSWORTH JD, BURRIS HA, MORRISSEY LH, LITCHY S, SCULLIN DC, BEARDEN JD, RICHARDS P, GRECO FA, Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;15:3052-3056.
6. CONCONI A, MARTINELLI G, THIEBLEMENT C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.